Open AccessTMAO reductase, a biomarker for gut permeability defect induced inflammation, in mouse model of chronic kidney disease and dextran sulfate solution-induced mucositis
Author(s) -
Sompong Boonhai,
Kanthika Bootdee,
Wilasinee Saisorn,
Kullaya Takkavatakarn,
Patita Sitticharoenchai,
Somkanya Tungsanga,
Khajohn Tiranathanagul,
Asada Leelahavanichkul
Publication year - 2023
Publication title -
asian pacific journal of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 33
ISSN - 0125-877X
DOI - 10.12932/ap-100321-1084
Subject(s) - kidney disease , inflammatory bowel disease , reductase , medicine , endocrinology , chemistry , biochemistry , disease , enzyme
The excretion of trimethylamine N-oxide (TMAO) (uremic toxin) into the intestine might be enhanced, due to the limited renal elimination in chronic kidney disease (CKD), possibly induced TMAO reductase (a TMAO-neutralizing enzyme) in gut bacteria. Detection of TMAO reductase in serum could be used as a biomarker of gut permeability defect.